GILD analyst scorecard · Gilead Sciences
45 rating changes on GILD in the last 12 months. 56% of bullish calls were right at 30 days; 50% of bearish ones. Street grade C on 40 scored calls. Consensus target $158, 9% above the last close.
Graded through 2026-09-14 · last close $145.59 (2026-09-14). Rebuilt every morning.
Holds on GILD, read: 1 cut to or raised to Hold (graded as the change) · 3 Holds whose target leaned 10%+ one way (graded that way) · 4 true Holds, not graded.
Firm by firm
| Firm | Calls | Scored | Right | Accuracy | Grade | Avg 30d | Avg 90d | Latest | Date | Target |
|---|---|---|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | 5 | 5 | 4 | 80.0% | A | +4.0% | +5.8% | Overweight | 2026-08-05 | $155 |
| Citigroup | 4 | 4 | 3 | 75.0% | A | +5.2% | -0.2% | Buy | 2026-04-13 | $165 |
| Morgan Stanley | 5 | 5 | 3 | 60.0% | B | +6.8% | +10.6% | Overweight | 2026-07-27 | $165 |
| Needham | 5 | 5 | 2 | 40.0% | D | -0.1% | +4.2% | Buy | 2026-08-05 | $170 |
| Truist Securities | 5 | 5 | 2 | 40.0% | D | -1.8% | -1.5% | Buy | 2026-07-07 | $156 |
| HSBC | 2 | 1 | 1 | — | — | +1.7% | — | Buy | 2026-09-10 | $175 |
| JPMorgan | 2 | 2 | 2 | — | — | +5.0% | +12.3% | Overweight | 2025-10-31 | $150 |
| UBS | 1 | 1 | 1 | — | — | +6.8% | -7.3% | Buy | 2026-01-26 | $155 |
| TD Cowen | 1 | 1 | 1 | — | — | +3.8% | +6.9% | Buy | 2025-10-23 | $125 |
| RBC Capital | 5 | 3 | 2 | — | — | +1.0% | +0.9% | Sector Perform | 2026-08-05 | $123 |
| Wells Fargo | 3 | 3 | 1 | — | — | -1.1% | +8.5% | Overweight | 2026-02-11 | $165 |
| Barclays | 2 | 0 | 0 | — | — | +0.2% | -13.8% | Equal-Weight | 2026-07-29 | $145 |
| Scotiabank | 2 | 2 | 0 | — | — | -5.6% | +5.5% | Sector Outperform | 2026-02-11 | $177 |
| Leerink Partners | 1 | 1 | 0 | — | — | +10.1% | — | Market Perform | 2026-07-21 | $127 |
| Maxim Group | 1 | 1 | 0 | — | — | -4.5% | +9.8% | Buy | 2026-05-20 | $165 |
| Jefferies | 1 | 1 | 0 | — | — | -4.4% | -13.8% | Buy | 2026-03-10 | $180 |
Dimmed rows have fewer than 4 scored calls on GILD — too few to grade.
Every call, last 12 months
| Date | Firm | Change | Action | Graded as | Price at call | Run before | +30d | +60d | +90d | Target · 90d check | Hit |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-10 | HSBC | Buy → Buy | maintained | Bullish | $144.81 | +6.7% | — | — | — | $175 | pending |
| 2026-08-05 | RBC Capital | Sector Perform → Sector Perform | maintained | True hold · target -6% | $131.76 | +1.7% | +14.6% | — | — | $123 | not graded |
| 2026-08-05 | Cantor Fitzgerald | Overweight → Overweight | reiterated | Bullish | $131.76 | +1.7% | +14.6% | — | — | $155 | ✓ |
| 2026-08-05 | Needham | Buy → Buy | reiterated | Bullish | $131.76 | +1.7% | +14.6% | — | — | $170 | ✓ |
| 2026-07-29 | Barclays | Equal-Weight → Equal-Weight | maintained | True hold · target +9% | $132.73 | +5.1% | +9.8% | — | — | $145 | not graded |
| 2026-07-27 | Morgan Stanley | Overweight → Overweight | maintained | Bullish | $130.52 | +2.1% | +13.5% | — | — | $165 | ✓ |
| 2026-07-21 | Leerink Partners | Outperform → Market Perform | downgrade | Bearish · cut to Market Perform | $130.28 | +5.3% | +10.1% | — | — | $127 | ✗ |
| 2026-07-08 | Morgan Stanley | Overweight → Overweight | maintained | Bullish | $135.82 | +6.0% | -1.9% | +8.0% | — | $166 | ✗ |
| 2026-07-07 | RBC Capital | Sector Perform → Sector Perform | maintained | Leans bearish · Sector Perform, target -12% | $136.36 | +5.6% | -4.0% | +7.5% | — | $120 | ✓ |
| 2026-07-07 | Truist Securities | Buy → Buy | maintained | Bullish | $136.36 | +5.6% | -4.0% | +7.5% | — | $156 | ✗ |
| 2026-07-06 | Cantor Fitzgerald | Overweight → Overweight | reiterated | Bullish | $129.61 | +0.3% | +1.7% | +16.5% | — | $155 | ✓ |
| 2026-07-06 | HSBC | Hold → Buy | upgrade | Bullish | $129.61 | +0.3% | +1.7% | +16.5% | — | $155 | ✓ |
| 2026-06-16 | Cantor Fitzgerald | Overweight → Overweight | reiterated | Bullish | $127.23 | -1.8% | +7.1% | +9.2% | +14.4% | $155 close | ✓ |
| 2026-05-20 | Maxim Group | Hold → Buy | upgrade | Bullish | $130.69 | -3.8% | -4.5% | +1.9% | +9.8% | $165 missed | ✗ |
| 2026-05-08 | Truist Securities | Buy → Buy | reiterated | Bullish | $131.33 | -7.2% | -2.5% | +3.8% | -0.4% | $157 missed | ✗ |
| 2026-05-08 | RBC Capital | Sector Perform → Sector Perform | maintained | True hold · target -7% | $131.33 | -7.2% | -2.5% | +3.8% | -0.4% | $122 missed | not graded |
| 2026-04-13 | Citigroup | Buy → Buy | maintained | Bullish | $139.03 | -4.1% | -4.3% | -9.7% | -5.5% | $165 missed | ✗ |
| 2026-04-10 | Morgan Stanley | Overweight → Overweight | maintained | Bullish | $138.99 | -4.8% | -3.9% | -9.7% | -3.0% | $175 missed | ✗ |
| 2026-03-10 | Jefferies | Buy | initiated | Bullish | $148.56 | -2.6% | -4.4% | -10.1% | -13.8% | $180 missed | ✗ |
| 2026-02-23 | Needham | Buy → Buy | reiterated | Bullish | $149.83 | +10.2% | -7.7% | -13.0% | -10.8% | $170 missed | ✗ |
| 2026-02-20 | Barclays | Equal-Weight | initiated | True hold · target +2% | $151.40 | +17.3% | -9.3% | -12.0% | -13.8% | $155 missed | not graded |
| 2026-02-11 | RBC Capital | Sector Perform → Sector Perform | maintained | Leans bearish · Sector Perform, target -24% | $155.80 | +27.1% | -6.9% | -10.8% | -13.4% | $118 close | ✓ |
| 2026-02-11 | Truist Securities | Buy → Buy | maintained | Bullish | $155.80 | +27.1% | -6.9% | -10.8% | -13.4% | $152 hit | ✗ |
| 2026-02-11 | Wells Fargo | Overweight → Overweight | maintained | Bullish | $155.80 | +27.1% | -6.9% | -10.8% | -13.4% | $165 missed | ✗ |
| 2026-02-11 | Cantor Fitzgerald | Overweight → Overweight | maintained | Bullish | $155.80 | +27.1% | -6.9% | -10.8% | -13.4% | $155 missed | ✗ |
| 2026-02-11 | Scotiabank | Sector Outperform → Sector Outperform | maintained | Bullish | $155.80 | +27.1% | -6.9% | -10.8% | -13.4% | $177 missed | ✗ |
| 2026-02-11 | Needham | Buy → Buy | maintained | Bullish | $155.80 | +27.1% | -6.9% | -10.8% | -13.4% | $170 missed | ✗ |
| 2026-01-27 | Truist Securities | Buy → Buy | maintained | Bullish | $140.97 | +13.1% | +2.0% | -3.3% | -9.4% | $145 missed | ✓ |
| 2026-01-27 | Citigroup | Buy → Buy | maintained | Bullish | $140.97 | +13.1% | +2.0% | -3.3% | -9.4% | $156 missed | ✓ |
| 2026-01-26 | UBS | Buy → Buy | maintained | Bullish | $137.78 | +10.5% | +6.8% | -2.6% | -7.3% | $155 missed | ✓ |
| 2026-01-13 | Morgan Stanley | Overweight → Overweight | maintained | Bullish | $121.76 | +1.1% | +24.7% | +19.3% | +14.2% | $150 close | ✓ |
| 2026-01-07 | Citigroup | Buy → Buy | maintained | Bullish | $124.35 | +2.6% | +22.6% | +17.9% | +11.6% | $140 hit | ✓ |
| 2025-12-12 | Morgan Stanley | Overweight → Overweight | maintained | Bullish | $120.40 | -2.4% | +1.8% | +22.3% | +20.6% | $151 hit | ✓ |
| 2025-12-10 | Wells Fargo | Overweight → Overweight | maintained | Bullish | $121.34 | +2.7% | -0.2% | +25.0% | +22.4% | $150 hit | ✗ |
| 2025-11-13 | Needham | Buy → Buy | maintained | Bullish | $125.20 | +5.7% | -4.3% | -2.1% | +24.4% | $140 hit | ✗ |
| 2025-11-13 | Scotiabank | Sector Outperform | initiated | Bullish | $125.20 | +5.7% | -4.3% | -2.1% | +24.4% | $140 hit | ✗ |
| 2025-11-03 | Truist Securities | Buy → Buy | reiterated | Bullish | $122.05 | +8.3% | +2.4% | -0.4% | +17.1% | $145 hit | ✓ |
| 2025-10-31 | Wells Fargo | Overweight → Overweight | maintained | Bullish | $119.79 | +7.8% | +3.8% | +2.8% | +16.5% | $145 hit | ✓ |
| 2025-10-31 | JPMorgan | Overweight → Overweight | maintained | Bullish | $119.79 | +7.8% | +3.8% | +2.8% | +16.5% | $150 close | ✓ |
| 2025-10-31 | RBC Capital | Sector Perform → Sector Perform | maintained | Leans bearish · Sector Perform, target -12% | $119.79 | +7.8% | +3.8% | +2.8% | +16.5% | $105 missed | ✗ |
| 2025-10-31 | Cantor Fitzgerald | Overweight → Overweight | reiterated | Bullish | $119.79 | +7.8% | +3.8% | +2.8% | +16.5% | $135 hit | ✓ |
| 2025-10-31 | Needham | Buy → Buy | reiterated | Bullish | $119.79 | +7.8% | +3.8% | +2.8% | +16.5% | $133 hit | ✓ |
| 2025-10-23 | TD Cowen | Buy → Buy | maintained | Bullish | $120.74 | +5.5% | +3.8% | +2.8% | +6.9% | $125 hit | ✓ |
| 2025-10-08 | Citigroup | Buy → Buy | maintained | Bullish | $118.25 | — | +0.5% | +2.5% | +2.6% | $135 missed | ✓ |
| 2025-09-16 | JPMorgan | Overweight → Overweight | maintained | Bullish | $110.86 | — | +6.3% | +11.9% | +8.1% | $145 missed | ✓ |
Also in Biotech
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How the grading works
Every sell-side rating change from the last 365 days is priced the day it lands and checked again 30, 60 and 90 days later. A call is a hit when the stock moved in the called direction at 30 days. Buy- and Sell-side ratings call their own direction. A Hold is read, not waved through: a downgrade to Hold is graded as a bearish call and an upgrade to Hold as a bullish one, and a maintained Hold whose price target sits 10%+ above the price leans bullish (10%+ below, leans bearish) and is graded that way. A Hold with a target close to the price is a true Hold and is not graded at all. Every call with a price target also gets a target check 90 days later: hit (reached it or within 5%), close (covered at least half the distance) or missed. A firm's accuracy on a single name prints only after 4 scored calls, and a firm gets its own page only after 10 scored calls across every covered name — below that a percentage is noise. "Run before the call" is the stock's move over the 30 calendar days before the rating landed. Data: Yahoo Finance rating history and daily closes, rebuilt each morning. Nothing on this page is advice.
Get the 7 AM brief
The AM take, today's docket and the Street's calls — one email, weekdays, before the open.